Atlas FDA

Praxis Extended RAS Panel

FDA premarket approval P160038 · decided 2017-06-29

Approval details

PMA number
P160038
Trade name
Praxis Extended RAS Panel
Generic name
Next generation sequencing oncology panel, somatic or germline variant detection system
Applicant
Illumina, Inc.
Date received
2016-09-02
Decision date
2017-06-29
Days to decision
300 days
Decision code
APWD
Product code
PQP
Advisory committee
Pathology
Expedited review
Yes
Location
San Diego, CA
Statement
Approval for the Praxis Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue samples. The Praxis™ Extended RAS Panel is indicated to aid in the identification of patients with colorectal cancer for treatment with Vectibix® (panitumumab

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
MISEQDX UNIVERSAL KIT 1.0 (DEN130042)Illumina, Inc.2013-11-19
ILLUMINA MISEQDX CYSTIC FIBROSIS 139-VARIANT ASSAY (K124006)Illumina, Inc.2013-11-19
ILLUMINA MISEQDX PLATFORM (DEN130011)Illumina, Inc.2013-11-19
ILLUMINA MISEQDX CYSTIC FIBROSIS CLINICAL SEQUENCING ASSAY (K132750)Illumina, Inc.2013-11-19
ILLUMINA BEADXPRESS SYSTEM (K093128)Illumina, Inc.2010-04-28
ILLUMINA VERNCODE GENOTYPING TEST FOR FACOR V AND FACTOR II (K093129)Illumina, Inc.2010-04-28